Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Albireo
- Target Recruit Count
- 52
- Registration Number
- NCT04674761
- Locations
- 🇫🇷
Antenne pédiatrique du CIC - Hopital Jeanne De Flandre, Lille, France
🇫🇷Hopital Necker Enfants Malades, Paris, France
🇹🇷Istanbul University Medical Faculty Hospital, Fatih, Turkey
Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Albireo
- Registration Number
- NCT04483531
- Locations
- 🇺🇸
Albireo Pharma Inc., Boston, Massachusetts, United States
A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Albireo
- Target Recruit Count
- 47
- Registration Number
- NCT04006145
- Locations
- 🇺🇸
Integrity Clinical Research, LLC, Doral, Florida, United States
🇺🇸Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States
Study of A4250 in Healthy Volunteers Under Fasting, Fed and Sprinkled Conditions
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Albireo
- Target Recruit Count
- 17
- Registration Number
- NCT03608319
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2
- First Posted Date
- 2018-06-25
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Albireo
- Target Recruit Count
- 62
- Registration Number
- NCT03566238
- Locations
- 🇺🇸
Johns Hopkins School of Medicine, Baltimore, Maryland, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇧🇪UZ Leuven, Leuven, Belgium
An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Albireo
- Target Recruit Count
- 6
- Registration Number
- NCT03082937
- Locations
- 🇬🇧
Quotient Clinical, Ruddington, Nottingham, United Kingdom
A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Albireo
- Target Recruit Count
- 94
- Registration Number
- NCT02963077
A4250, an IBAT Inhibitor in Pediatric Cholestasis
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Albireo
- Target Recruit Count
- 24
- Registration Number
- NCT02630875
- Locations
- 🇩🇪
Gastroenterology/Hepatology, University Hospital for Children and Adolescents, Tuebingen, Germany
🇸🇪Henrik Arnell, Stockholm, Sweden
🇬🇧King's College Hospital NHS Foundation Trust, London, United Kingdom
Double-blind, Randomised Study of A3384 in BAM/BAD
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Albireo
- Target Recruit Count
- 19
- Registration Number
- NCT02078856
- Locations
- 🇸🇪
Kärnsjukhuset, Skövde, Sweden
🇸🇪Sahlgrenska Academy, Göteborg, Sweden
🇬🇧Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
Study of A3309 in Patients With Dyslipidemia
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Albireo
- Target Recruit Count
- 36
- Registration Number
- NCT01069783
- Locations
- 🇸🇪
BCRC, Linköping, Sweden